BioLineRx (BLRX) Shares Outstanding (Weighted Average) (2013 - 2025)

BioLineRx's Shares Outstanding (Weighted Average) history runs 13 years deep, the most recent figure standing at $73.4 million for Q4 2025.

• In Q4 2025, Shares Outstanding (Weighted Average) rose 92.74% year-over-year to $73.4 million; the TTM figure through Dec 2025 stood at $73.4 million (up 92.74% YoY), while the FY2025 annual figure was $73.4 million, up 92.74% from the prior year.
• Shares Outstanding (Weighted Average) was $73.4 million for Q4 2025 at BioLineRx, roughly flat from $73.4 million in the prior quarter.
• In the past five years, Shares Outstanding (Weighted Average) ranged from a high of $1.1 billion in Q1 2024 to a low of $21.1 million in Q1 2022.
• Historically, Shares Outstanding (Weighted Average) has averaged $391.3 million across 5 years, with a median of $73.4 million in 2025.
• The sharpest annual moves came in 2023 and 2024: Shares Outstanding (Weighted Average) jumped 4281.27% in 2023, then plunged 96.49% in 2024.
• A 5-year view of Shares Outstanding (Weighted Average) shows it stood at $662.9 million in 2021, then jumped by 39.22% to $923.0 million in 2022, then grew by 17.73% to $1.1 billion in 2023, then slumped by 96.49% to $38.1 million in 2024, then soared by 92.74% to $73.4 million in 2025.
• The last three Shares Outstanding (Weighted Average) figures came in at $73.4 million (Q4 2025), $73.4 million (Q3 2025), and $71.8 million (Q2 2025), per Business Quant data.